Originally a research and development company focused on technology, Positron’s business strategy has evolved over the past 3 years from an imaging device manufacturer to a company that provides a comprehensive “full nuclear cardiology solution”. Positron is actively pursuing key initiatives to ensure the growth and longevity of the company, as well as, the industry by securing the supply of key isotopes, providing necessary radiopharmaceuticals that apply to both PET and SPECT imaging modalities and offering attractive financing solutions. We strive to maximize market share by offering cost-effective, value added solutions to end-users, with the objective of becoming a sustained long-term value creator for industry participants and shareholders.
// dedicated PET system optimized for myocardial perfusion imaging, that enables physicians to provide superior
proven technology, while delivering an accurate diagnosis.
// our manufacturing facility is optimized for Positron’s proprietary and third party manufactured PET & SPECT
// the acquisition of MIT enables Positron to enter the radiopharmaceutical market via recycling spent Sr-82/Rb-82
generators and production from foreign suppliers.